Answered on the record on 30 October 2026, from the files as they stood that day Went up
Benitec Biopharma rises furthest of the drugmakers in the record, its three tenses running from 2.4 in the past to 7.9 in the future, followed by Kala Bio, from 2.0 to 7.2. The ten below lead the part of the family's 497 graded drugmakers whose tenses rise end to end, among those with more than three metrics read as filed.
How this list was made. By the screener's direction rule, a company rises when its tenses never fall from past to present to future and its future is more than half a point above its past. The tenses come from the family report of 29 October 2026 for Pharmaceutical Preparations, industry code 2834; only companies with more than three of the nine metrics read as filed count. The ten that rise furthest are listed, ties by headline, highest first; a rising arc is the record's reading of the company, never a price or a move.
- BNTCBenitec Biopharma Inc. past 2.4, present 5.5, future 7.9Its three tenses rise end to end, from 2.4 in the past to 7.9 in the future. The headline is 5.7 of 10, with 5 of the nine metrics read as filed and 4 CrossAssetData estimates.
- KALAKala Bio, Inc. past 2.0, present 2.7, future 7.2Its three tenses rise end to end, from 2.0 in the past to 7.2 in the future. The headline is 4.3 of 10, with 5 of the nine metrics read as filed and 4 CrossAssetData estimates.
- KPRXKiora Pharmaceuticals, Inc. past 1.9, present 5.3, future 6.4Its three tenses rise end to end, from 1.9 in the past to 6.4 in the future. The headline is 4.9 of 10, with 4 of the nine metrics read as filed and 5 CrossAssetData estimates.
- PHIOPhio Pharmaceuticals Corp. past 1.3, present 4.6, future 5.2Its three tenses rise end to end, from 1.3 in the past to 5.2 in the future. The headline is 4.0 of 10, with 5 of the nine metrics read as filed and 4 CrossAssetData estimates.
- ERNAErnexa Therapeutics Inc. past 1.2, present 1.7, future 5.1Its three tenses rise end to end, from 1.2 in the past to 5.1 in the future. The headline is 2.9 of 10, with 7 of the nine metrics read as filed and 2 CrossAssetData estimates.
- VTVTvTv Therapeutics Inc. past 3.4, present 4.8, future 6.9Its three tenses rise end to end, from 3.4 in the past to 6.9 in the future. The headline is 5.3 of 10, with 4 of the nine metrics read as filed and 5 CrossAssetData estimates.
- SYRESpyre Therapeutics, Inc. past 2.7, present 6.0, future 6.2Its three tenses rise end to end, from 2.7 in the past to 6.2 in the future. The headline is 5.2 of 10, with 4 of the nine metrics read as filed and 5 CrossAssetData estimates.
- FBRXForte Biosciences, Inc. past 3.3, present 3.7, future 6.8Its three tenses rise end to end, from 3.3 in the past to 6.8 in the future. The headline is 4.9 of 10, with 7 of the nine metrics read as filed and 2 CrossAssetData estimates.
- VTGNVistaGen Therapeutics, Inc. past 3.0, present 4.0, future 6.5Its three tenses rise end to end, from 3.0 in the past to 6.5 in the future. The headline is 4.8 of 10, with 8 of the nine metrics read as filed and 1 CrossAssetData estimate.
- DAREDare Bioscience, Inc. past 3.2, present 3.4, future 6.7Its three tenses rise end to end, from 3.2 in the past to 6.7 in the future. The headline is 4.7 of 10, with 8 of the nine metrics read as filed and 1 CrossAssetData estimate.
Left out as thin
Three companies with thin records rise further than the list's last row: Revelation Biosciences, from 2.6 to 6.4, GRI Bio, from 2.8 to 6.5, and MetaVia, from 2.8 to 6.4. Each has only 2 or 3 of the nine metrics read as filed, so the report marks them thin and the list leaves them out.
By the desk, an AI model, from the record alone (ruling 162). Every figure is a field of the files named above, matched by value when the answer was staged. Nothing here is advice, and nothing here is a price.
Ask your own question → Every answer